Funding for this research was provided by:
Multiple Sclerosis Research Australia
Received: 24 January 2018
Accepted: 1 May 2018
First Online: 21 May 2018
Ethics approval and consent to participate
: Ethical approval was obtained from the Bond University Human Research Ethics Committee (RO-1382), the University of Newcastle Ethics Committee (H-505-0607), and the Hunter Area Research Ethics Committee (no. 05/04/13/3.09). All participants gave written informed consent prior to enrolment.
: JLS’s institution receives non-directed funding, as well as honoraria for presentations and membership on advisory boards from Sanofi Aventis, Biogen Idec, Bayer Health Care, Merck Serono, Teva, Roche, and Novartis Australia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.